Unveiling 6 Analyst Insights On Capricor Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts' ratings for Capricor Therapeutics (NASDAQ:CAPR) over the last quarter show a mix of bullish and somewhat bullish sentiments. The average 12-month price target has decreased by 8.45%, with a high estimate of $40.00 and a low estimate of $8.00. Key analysts have maintained or raised their ratings, reflecting their reactions to recent developments.
July 02, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts' ratings for Capricor Therapeutics (NASDAQ:CAPR) show a mix of bullish and somewhat bullish sentiments. The average 12-month price target has decreased by 8.45%, with a high estimate of $40.00 and a low estimate of $8.00. Key analysts have maintained or raised their ratings, reflecting their reactions to recent developments.
The mixed analyst ratings and the decrease in the average price target suggest a neutral short-term impact on CAPR's stock price. While some analysts maintain or raise their ratings, the overall sentiment has slightly shifted negatively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100